	US 12,410,447 B2
	Engineered muscle targeting compositions
Pardis Sabeti, Cambridge, MA (US); Mohammadsharif Tabebordbar, Cambridge, MA (US); and Simon Ye, Cambridge, MA (US)
Assigned to The Broad Institute, Inc., Cambridge, MA (US); President and Fellows of Harvard College, Cambridge, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by The Broad Institute, Inc., Cambridge, MA (US); President and Fellows of Harvard College, Cambridge, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Oct. 15, 2024, as Appl. No. 18/915,537.
Application 18/915,537 is a continuation of application No. 17/764,509, previously published as PCT/US2020/056133, filed on Oct. 16, 2020.
Claims priority of provisional application 63/055,252, filed on Jul. 22, 2020.
Claims priority of provisional application 63/018,454, filed on Apr. 30, 2020.
Claims priority of provisional application 62/916,207, filed on Oct. 16, 2019.
Claims priority of provisional application 62/916,221, filed on Oct. 16, 2019.
Prior Publication US 2025/0051800 A1, Feb. 13, 2025
Int. Cl. C12N 15/86 (2006.01); A61K 31/7088 (2006.01); A61K 47/64 (2017.01); A61K 48/00 (2006.01); C07K 7/06 (2006.01); C07K 14/005 (2006.01); C07K 14/47 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/861 (2006.01)

CPC C12N 15/86 (2013.01) [A61K 31/7088 (2013.01); A61K 47/6435 (2017.08); A61K 48/0066 (2013.01); C07K 7/06 (2013.01); C07K 14/005 (2013.01); C07K 14/47 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C07K 2319/01 (2013.01); C12N 2310/20 (2017.05); C12N 2750/14122 (2013.01); C12N 2750/14123 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14145 (2013.01); C12N 2800/80 (2013.01); C12N 2810/405 (2013.01); C12N 2810/6027 (2013.01); C12N 2830/008 (2013.01)]

30 Claims

1. A composition comprising a targeting moiety effective to target a muscle cell, wherein the targeting moiety comprises an n-mer motif comprising X_mRGDYX₁X₂L,

wherein X is selected from any amino acid, and wherein m is 0-4.